Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Arpraziquantel ODT in Schistosoma Infected Children
NCT03845140Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Sep 2019
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of levopraziquantel in schistosomiasis, sponsored by Merck KGaA. Started Sep 2019; status: completed.
02
Drugs
levopraziquantel
03
Conditions
schistosomiasis
Beyond the preview
Go deeper on NCT03845140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03845140.